Transcription
In 1987, American Airlines saved ₹40,000. That's more than $1 crore in a single year. These figures are inflation-adjusted, of course, and they achieved this without firing anyone, without changing a single route, and without buying a new aircraft. So, how did they do it? They removed one olive from every first-class salad. One olive. That story became a legend in aviation circles because it captured something true about this industry: every gram matters.
Now, Indigo figured this out pretty early. A standard aircraft oven weighs 30 kg. Multiply that across 400 planes. That's 12,000 kg of dead weight gone. But by just serving you a cold sandwich, they are saving crores of rupees. They will lose an oven, pull an olive, and charge you ₹500 for an extra kilo of luggage. But the person carrying those extra kilos, that's not in their control, and it's their biggest drain. There are so many posts about it on Reddit. So, what would it take to finally fix that?
Airlines have tried everything. Lighter seats, pepleless, cockpits, carbon fiber meal trays – they've tried it all, but nothing moves the needle like the passengers themselves. And so today, I am going to tell you about a diabetes drug that is quietly doing it for them. Ozempic. What if you lose weight with Ozempic? He doesn't know Ozempic and Mounjaro. And I got my first shot of Mounjaro. It's madness, Ozempic, man. So what happened? Hi, Marun, and you are watching How Bazaar. So let's begin.
To understand why a diabetes drug matters to an airline, you first need to understand one simple truth about aviation: that everything that goes up must be lifted, and lifting things burns fuel. The heavier the aircraft, the harder the engines work, and the more fuel they burn. It's the same reason your car gives worse mileage when it's fully loaded. For an aircraft like the Airbus A320, which, by the way, Indigo has about over a hundred of them, the maximum take-off weight is around 75,000 kg. That number includes the aircraft itself, the fuel, the bags, and the passengers.
Here's the thing that surprises most people. Passengers and their baggage make up roughly 23% of that total weight. Almost a quarter of what the aircraft is lifting through the sky is human beings and their luggage. The aircraft, the engines, the seats – all of that is fixed weight. Once Indigo buys a plane, that number doesn't move. Fuel changes by route. Cargo is still manageable. But passengers? After 100 years of aviation, nobody has cracked that one. Jack Evans, who is the spokesperson for the Air Transport Association of America, put it best in an interview with NBC News way back in 2004: "Just like we don't control the costs of our fuel, we don't control the weights of our passengers." Passengers gain weight, but airlines are the ones that go on a diet.
So, I went digging. Indigo is a listed company. They filed detailed results with the stock exchange every quarter. I pulled their FY25 annual report and I went line by line through the expense breakdown, and then I found it: ₹26,197 crore. Just fuel out of expenses of ₹76,500 crore. That is 34.2% of every rupee Indigo spent in FY25. More than employees, more than maintenance, more than airport charges and depreciation combined. One line item bigger than everything else. If even 1% of that comes down, then you are talking about almost ₹260 crore falling straight to the profit. And that too, without a single operational change. That is a price.
Now, let's talk about the drug that might deliver it. Before we get into the exact numbers, here's a quick setup. The drugs at the center of this story are a class called GLP-1 receptor agonists. You know the brand names: Ozempic, Wegovy, Mounjaro. Originally, they were built to manage Type 2 diabetes. Cut to today, they are among now the fastest-selling drugs on the planet, and their effect on human bodies is about to become accidentally one of the most interesting aviation finance stories in years.
Before we get to the math, I want to take a step back. Because to understand why this drug changes the fuel equation, you need to understand what this drug actually does inside your body. And for that, I spoke to a doctor who prescribes it. Because this isn't Calcium Sandoz that anyone can pick up from a pharmacy and take. At 100, if you are using it for a year or so, the weight comes down to 80. That is Dr. Saptarshi Bhattacharya, who is a top endocrinologist at Apollo Hospitals, New Delhi. How do semaglutides and GLP-1 actually work? So, this is a hormone. Once we have food, it will send a signal to the brain and will tell us when to stop.
How did this drug come into existence? Like, how did it start and how did we come here now? I can see so many celebrities taking it. This hormone actually came from, uh, there is a monster. There is a type of, uh, called Gila monster. That's a reptile. So they had this chemical called exendin in their saliva, which helps in regulating glucose. So when they were experimenting with all these things, they found that it has a glucose-lowering property. Then this was researched further, and they found this group of molecules called GLP-1. And almost for 10-15 years, we have used this, uh, molecule for diabetes control and also partly for controlling weight.
When patients of yours end up taking semaglutides or GLP-1 and so on, like, what do they describe the effect as? Cravings for sweets go down. So this is something which is reported and known. Nausea is a known side effect of this molecule, the nausea or the vomiting tendency that that goes up. But it's very important that you maintain the protein balance with this molecule, otherwise, there can be some amount of muscle loss also. You listed a number of side effects that come with taking GLP-1, right? What are some long-term effects of taking it? Like, I understand patients, you mentioned, have taken it for six months, one year. What about, you know, over an extended period of time? See, if it's for diabetes, diabetes medications do continue because diabetes is a progressive disease. If it's for obesity, and if somebody has reached their target weight, say, has lost 20-30 kg, it totally depends on him or her how they are going to maintain that weight in the future. So there are people who have stopped it and are able to maintain it by lifestyle changes because now they are more agile and they are able to exercise more. Even if somebody develops, say, pancreatitis-like symptoms, which is like abdominal pain radiating to the back. So these are things which we need to discuss with our patients. Because this is seen as such a miracle drug, and everyone is tempted to try it out. Often, they do this without a proper prescription. I think that is something which is really cause for concern. So it has to be done under the supervision of a specialist. So you, it's not an over-the-counter drug. So some, so we have people who have taken this, and they had major episodes of vomiting, landed up in the emergency. So it does happen. So maybe one out of 15 or one out of 20 will not be able to tolerate it because just because of gastric issues. Somebody is having difficulty in tolerating. So we usually, what we do is, we gradually step up the dose over, like, once every four weeks or so. So we go slow with that. So it requires counseling and monitoring at each and every step. It, it can't be a standalone miraculous treatment. Okay, you take it for two weeks or three weeks to lose it. So when we have a discussion, we do tell somebody that we are looking at six months or one year if somebody is planning to do it. There is no point in taking it for one to two months. It's not a miracle. If you take it, you stop it after one to two months, it is definitely going to come back. Going to wellness centers, going to gyms, going to all sorts of places, and there, everybody is just selling Mounjaro or Ozempic. So, and people used to get it from Dubai also when it was not even available in India. So, so they get it imported at almost double or triple the cost from there. Oh, that I didn't know. Insane. Okay, okay. Instead of iPhones, now people are getting Mounjaro from Dubai. We have so many people who actually were on Mounjaro. Even so, it got launched around a year back, around this time last year. And we, there are people in 2024 or 2023 who used to get Mounjaro from Dubai. And like practicing endocrinologists, and most of our patients are for diabetes. So most of endocrinologists, most, so our main practice is diabetes. So we have so many patients who are just waiting for the patent to go off. So they may be, once the molecule, the dose, the cost will be like ₹2,000 per month. Now the current cost is like ₹10,000 per month. And they anyway, they are paying another ₹5,000, ₹8,000 for their other medications for diabetes.
All of this just got me thinking. I knew to read up a bit more. In January 2026, Wall Street firm Jefferies put out a research note, not about pharma, not about obesity, about airlines. Their finding was that if the average American passenger loses just 10% of their body weight, the four biggest US carriers save ₹580 million a year in fuel. In rupees, that's more than ₹5,000 crore. That is roughly 4% added to the earnings per share from passengers quietly getting lighter. Or in war-like situations, fuel costs skyrocket, which recently happened due to the war in the Middle East.
I read that research note and immediately thought two things. One, what does this number look like for Indigo? And two, and I want to be upfront about this, the Jefferies report is talking about a 10% weight drop across an entire population. That is not guaranteed. These drugs work, and the clinical data is strong. But we are talking about mass adoption of a medication that is relatively new. COVID throwback. The long-term picture is still uncertain. We are running a thought experiment here, not a prophecy. But the thought experiment itself is worth running. So I did. Let's make a guess on this, right? So, Indigo has 434 aircrafts as of 31st March 2025, from the same annual report. 118.6 million passengers in FY25. Not one of them was weighed before boarding. Let's understand the math. Let's see each passenger loses around 7 kg. That is, by the way, well within what the Step One trial shows that semaglutide delivers. Now let's apply that to 180 passengers per flight. Applied against a 75,000 kg aircraft. Aviation zone's thumb rule says that every 1% weight reduction saves 0.75% fuel. Run it through, multiply by current ATF prices, that's around ₹13 per kilogram, and you get ₹39 crore per year for Indigo's entire fleet for free, zero effort. Now let's see each passenger loses around 10 kg, which the clinical data shows is entirely achievable. That figure touches ₹41 crore. So essentially, you can see anywhere between ₹300 to ₹400 crore a year as an airline. To put that in context, I checked this too. Indigo's entire annual ad spend in FY25 was ₹142 crore. We are talking about savings that are three times their entire marketing budget, and nobody in their finance team had to do a thing.
Here is where it gets specifically Indian and specifically right now. Hey, this is Arunima from the future. As you can probably tell from the haircut, I wanted to give a quick update about the story because the video in the studio was shot four days before March 20th. March 20th is the date, no, no, the patent on semaglutide expired. And I wanted to explain what that meant for India, a country which provides generic medicines to the entire world. So, essentially, the very next day, the big boys of the pharma industry went to war. Natco Pharma introduced its own generic version of the drug, which was priced at around ₹320, and you need to have it on a weekly basis. Dr. Reddy's dropped their own version, it's called Obelia. They priced it around ₹420, and you need to have it every single week. Even Zydus's Semaglide, which is a reusable multi-dose pen, is around the same highly competitive bracket. I actually checked this on Tata 1MG, and I want to show you the impact. Look at this, like everything is sold out in just a matter of hours. People were acting like it was some iPhone flash sale. The demand was through the roof. Before March 20th, the price of Ozempic and Wegovy was around ₹10,000 a month. Then analysts predicted that after this patent expires, it would come down to around ₹3,500 a month. But now, as you can see, the prices are even lower. Let's put ₹1,290 a month into perspective. A monthly membership of Cultpass Elite by Cultfit is around ₹4,000. So generic semaglutide is roughly one-third the price of a monthly gym membership. At this price point, it stops being something that only the rich can afford. Anyone who is a working urban middle-class professional in India who takes Indigo, you know, once or twice a month for work purposes alone, is going to be able to afford this. This was the update. Now back to the studio.
So far, a clean win for airlines, but I kept pulling on this thread. When understanding how GLP-1 works, I get that you can't separate the appetite suppression from the weight loss. They are basically the same mechanism. And I started wondering, what does appetite suppression mean inside a metal tube at 35,000 feet? In-flight food is not a hunger business. Nobody boards a two-hour flight starving. It's actually an impulse business. You board, you're stuck, a trolley rolls by, something smells fine, and you tap your card. That is the entire model. So, I went back to the same Indigo annual report because everything in the story lives in that one document. In-flight stock purchase FY25: ₹383 crore. That is just what Indigo paid to buy the food. The revenue from selling it to you is a significant multiple of that number. High margins, captive audience, no competition in the sky. Even for that "jungli" sandwich. As GLP-1 adoption grows, a quietly growing share of passengers simply will not want anything from that trolley. The food noise is gone before they even bought. That ₹383 crore cost line will compress. Yes. But the revenue it was generating, which is a significant multiple of that cost, will compress faster. If you compare the two, the fuel saving is larger. This does not flip the equation. But it is a real trade-off sitting right inside what looks like a clean win. And as far as I can tell, no airline CFO is modeling for it yet. One drug, two effects. You get one, and you accept the other.
Two things, both good news for airlines. First, maintenance. Every landing is a controlled collision. Brakes, tires, and landing gear. The heavier the aircraft, the faster they wear. If there are lighter passengers, and considering there are thousands of landings, there are extended maintenance cycles. This quietly compounds into real money. And then, that meme angle. Indigo charges you ₹500 for one extra kilo of baggage. No negotiation. The person next to you could be 40 kg heavier, but doesn't have to pay a single rupee. Airlines silently absorb all of it. GLP-1 drugs gradually narrow that gap. No announcement, no PR disaster. That cost just quietly disappears.
Here's what I keep coming back to. No pharmaceutical company designed Ozempic with airlines in mind. No aviation executive lobbied for GLP-1 adoption. This is a completely accidental connection. But accidental connections are often the most interesting kind in economics. We did the math. A 1% fuel saving at Indigo is around ₹260 crore. And the timing could not be more precise. Generic semaglutide is hitting Indian shores at exactly the moment India's aviation market is adding millions of new flyers every year. Right as India's aviation industry goes through its biggest expansion ever, Indigo alone is targeting a fleet of 600-plus aircrafts by the end of this decade. Generic semaglutide is about to become genuinely affordable for the Indian middle class. The same person who flies Indigo twice a month for work, who is managing their diabetes, and who just got a prescription from their doctor. They are going to lose weight for their own reasons. And somewhere in the background, quietly, the load sheet of their flight will go down by a kilogram or two. The fuel truck will pump slightly less Aviation Turbine Fuel, or ATF. And Indigo's quarterly results will show a small, unexplained improvement in fuel efficiency that no analyst quite knows how to attribute.
And one more thing before I let you go. Because I know this story is exciting, but again, at the same time, I don't want the ambiguity to be lost in this excitement. Semaglutide is still a young drug in population terms. The data on long-term use in non-diabetic people is genuinely incomplete. Doctors are already flagging concerns about muscle mass loss and what happens when people stop taking it. About side effects we haven't tracked for a decade yet. The aviation finance story is real. The math checks out. But it's built on the assumption of mass adoption of a drug whose full profile we do not know yet. This is an accident. A diabetes drug accidentally solving an airline cost problem. But accidents, good and bad, have consequences we do not fully see until much, much later. The olive was worth thousands. This drug could be worth billions. That's it for today. If this made you see something familiar in a completely new way, that is exactly what How Bazaar is here for. I am Arunima Rao. See you in the next one. Until then, stay curious. Done. Let's go.